Armed Forces Institute of Pathology (AFIP), Rawalpindi, Pakistan
The objective of this descriptive study was to determine Felis domesticus (cat) and Canis familiaris (dog) protein epitopes that bind strongly to selected HLA class II alleles to identify synthetic vaccine candidate epitopes and to identify individuals/populations who are likely to respond to vaccines. FASTA amino acid sequences of experimentally validated allergenic proteins of house cat and dog were identified using International Union of Immunological Societies (IUIS) allergen nomenclature database. NetMHCII 2.2 server was used to determine binding affinities in the form of 1-log 50 k and in nM with commonly found HLA II alleles. Screening of house cat and dog allergenic proteins identified 4 (with 2 isoforms for chain 1 and 3 isoforms for chain 2 for fel d 1) and 6 proteins, respectively. Number of strong binders from each protein against each HLA type was determined as potential candidate for allergen immunotherapy. HLA-DRB1*0101 bound maximum number of epitopes (207 and 275 from house cat and dog, respectively) while HLA-DRB1*0802 bound none. We conclude that HLA specific epitope prediction can help identify synthetic peptide vaccine candidates and predict response as well.
Asher, MI; Montefort, S; Björkstén, B; Lai, CK; Strachan, DP; Weiland, SK; Williams, H and ISAAC Phase Three Study Group (2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic rhino-conjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 368: 733-743.
Bateman, ED; Hurd, SS and Barnes, PJ (2008). Global strategy for asthma management and prevention: GINA executive summary. Europ. Resp. J., 31: 143-178.
Berlin, C; Kowalewski, DJ; Schuster, H; Mirza, N; Walz, S; Handel, M; Schmid-Horch, B; Salih, HR; Kanz, L; Rammensee, HG; Stevanovic, S and Stickel, JS (2014). Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia, 30: 1003-1004.
Douglas, G; Higgins, B and Barnes, N (2008). British guideline on the management of asthma: a national clinical guideline. Thorax. 63: iv1-iv121.
Hafner, R; Couroux, P; Armstrong, K; Patel, D; Larche, M and Haumann, B (2013). Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immune-regulatory epitopes. Clin. Transl. Allergy. S3: O7.
Immonen, A; Farci, S; Taivainen, A; Partanen, J; Pouvelle-Moratille, S; Narvanen, A; Kinnunen, T; Saarelainen, S; Rytkonen-Nissinen, M; Maillere, B and Virtanen, T (2005). T cell epitope-containing peptide of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J. Immunol., 175: 3614-3620.
Lowe, L; Custovic, A and Woodcock, A (2004). Childhood asthma. Curr. Allergy Asthm. R., 4: 159-165.
Moldaver, D and Larche, M (2011). Immunotherapy with peptides. Allergy. 66: 784-791.
National Asthma Education and Prevention Program (2007). Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J. Allergy Clin. Immunol., 120: S94-S138.
Nielsen, M and Lund, O (2009). NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 10: 296- 306.
Nielsen, M; Lundegaard, C and Lund, O (2007). Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 8: 238-250.
Oseroff, C; Sidney, J; Vita, R; Tripple, V; McKinney, DM; Southwood, S; Brodie, TM; Sallusto, F; Grey, H; Alam, R; Brodie, D; Greenbaum, JA; Kolla, R; Peters, B and Sette, A (2012). T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J. Immunol., 189: 1800-1811.
Park, H; Ahn, K; Park, MH and Lee, SI (2012). The HLA-DRB1 polymorphism is associated with atopic dermatitis, but not egg allergy in Korean children. Allergy Asthma Immunol. Res., 4: 143-149.
Prescott, SL and Tang, MLK (2005). The Australasian Society of Clinical Immunology and Allergy position statement: summary of allergy prevention in children. Med. J. Aust., 182: 464-467.
Prickett, SR; Voskamp, AL; Phan, T; Dacumos-Hill, A; Mannering, SI; Rolland, JM and O’Hehir, RE (2013). Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin. Exp. Allergy. 43: 684-697. doi: 10.1111/cea.12113.
Sirskyj, D; Diaz-Mitoma, F; Golshani, A; Kumar, A and Azizi, A (2011). Innovative bioinformatics approaches for developing peptide based vaccines against hypervariable viruses. Immunol. Cell Biol., 89: 81-89.
TePas, EC; Litonjua, AA; Celedón, JC; Sredl, D and Gold, DR (2006). Sensitization to aeroallergens and airway hyper responsiveness at 7 years of age. Chest. 129: 1500-1508.
Tipu, HN and Ahmed, D (2014). Differential binding of Aspergillus fumigatus allergenic proteins to human leuko-cyte antigen (HLA) alleles in dry lab: potential for immunotherapy. Cell. Biol.: Res. Ther., 3(1). doi: 10.4172/ 2324-9293.1000111.
Tipu, HN; Ahmed, TA and Bashir, MM (2011). Human leukocyte antigen class II susceptibility conferring alleles among non-insulin dependent diabetes mellitus patients. J. Coll. Physicians Surg. Pak., 21: 26-29.
Tipu, HN; Babar, ME and Hussain, T (2014). Binding affinities of dengue virus envelope glycoprotein residues with human leukocyte antigen alleles: dry lab candidates for synthetic vaccines. Life Sci. J., 11: 552-557.
Tomar, N and De, RK (2010). Immunoinformatics: an integrated scenario. Immunology. 131: 153-168.
Wand, P; Sidney, J; Kim, Y; Sette, A; Lund, O and Nielsen, M (2010). Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 11: 568-580.
Whelan, FJ; Yap, NVL; Surette, MG; Golding, GB and Bowdish, DME (2013). A guide to bioinformatics for immunologists. Front. Immunol., 4: 1-16.
Worm, M; Lee, HH; Kleine-Tebbe, J; Hafner, RP; Laidler, P; Healey, D; Buhot, C; Verheof, A; Maillere, B; Kay, AB and Larche, M (2011). Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J. Allergy Clin. Immunol., 127: 89-97.